InflammaSenseという医療機器メーカーは、ARPA-Hから最大で3800万ドルの資金援助を受けることになりました。この資金は、そのVITALx-patchというウェアラブルセンサーとARC cascade-endotyping分類器を使用して、重篤な病患者の自律神経および炎症サインをモニタリングするためのものです。
なぜ重要か. この技術は、敗血症などの重大な病気の検出と治療を改善でき、命を救い、医療費を削減する可能性があります。
InflammaSense is a pre-revenue medtech company based in La Jolla, California, developing autonomic neurography (ANG) technology for real-time immune monitoring.
InflammaSense joins the program as a subaward performer under prime awardee the University of Vermont, working alongside UVM's Gary An on the ReSCUED effort within CIRCLE.
InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology
InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology, today announced its selection as a performer on an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program receiving up to $38M to transform how clinicians…
Under the subaward, InflammaSense will deploy its VITALx-patch, a non-invasive wearable sensor, to measure autonomic and inflammatory signatures in up to 200 severely critically ill patients across three clinical sites. Data will feed the company's Autonomic Research Core (ARC)…
LA JOLLA, Calif., Oct. 7, 2026 /PRNewswire/ -- InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology, today announced its selection as a performer on an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program r…
